Fuzeon
(Enfuvirtide)ApprovedPeptide
Enfuvirtide is used to treat HIV infection by blocking the virus from entering and infecting CD4 cells, which are important immune cells. It is typically used in combination with other HIV medications, especially for patients whose virus has become resistant to other drugs.[2] Fuzeon is currently approved and in use across 5 indications[4].[1]
Fuzeon is one of 173 small molecule programs targeting Viral Disease. It is currently in Approved.
5
Indications
30
Total Trials
0
Active Trials
172
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
123 competitors in HIV Infection
#DrugCompanyPhaseTrials
1Arava
SanofiApproved
Mycobutin
PfizerApproved
Cabenuva
GSKApproved
Golytely
BayerApproved
Hepsera
GileadApproved
Zofran
NovartisApproved
Viread
GileadApproved
Incivek
Vertex PharmaceuticalsApproved
Lotrimin
BayerApproved
Zometa
PfizerApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Immunodeficiency7 trials
Treatment4 trials
Optimizing Treatment for Treatment-Experienced, HIV-Infected People
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00537394·517 enrolled
Adult3 trials
HIV2 trials
Intensification With Enfuvirtide in Naive HIV-infected Patients (ANRS130)
Completed·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 3·NCT00302822·195 enrolled
13 more indications
HIV-1 infection1 trial
HIV-11 trial
AIN1 trial
Children1 trial
Study of a New Anti-HIV Drug, T-20, in HIV-Infected Children
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00001118·24 enrolled
Efficacy1 trial
Combination Therapy1 trial
Resistance1 trial
Encephalopathy1 trial
Allogeneic Hematopoietic Stem Cell Transplantation1 trial
Optimized Antiretroviral Therapy During Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Individuals
Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT01836068·11 enrolled
Drug1 trial
Adding New Drugs for HIV Infected Patients Failing Current Therapy
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT00031044·50 enrolled
Unspecified1 trial
Regulatory
FDA Approval Timeline[5]
Mar 13, 2003
FUZEON
NDA NDA021481
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Fuzeon drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Enfuvirtide. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Transmembrane Glycoprotein Gp41 Inhibitor[3]
- Modality
- Peptide[3]
- Highest Phase
- Approved[1]
- Company
- CConrado Roberto Hoffmann Filho